Compare NRDY & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRDY | RLYB |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.0M | 92.9M |
| IPO Year | 2020 | 2021 |
| Metric | NRDY | RLYB |
|---|---|---|
| Price | $0.83 | $16.03 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 938.1K | 43.7K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.16 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $858,000.00 |
| Revenue This Year | $4.88 | N/A |
| Revenue Next Year | $10.03 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 43.00 |
| 52 Week Low | $0.75 | $0.40 |
| 52 Week High | $1.74 | $17.57 |
| Indicator | NRDY | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 41.34 | 60.85 |
| Support Level | $0.78 | $15.60 |
| Resistance Level | $1.00 | $16.50 |
| Average True Range (ATR) | 0.07 | 0.37 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 9.04 | 55.62 |
Nerdy Inc operate a next-generation live tutoring and intervention platform that leverages the power of human expertise with Developed artificial intelligence (AI) to personalize learning, accelerate student achievement, and empower educators. The company's proprietary platform leverages technology, including AI, to connect learners with instructors across a wide range of subjects and formats, including subscription-based learning, one-on-one instruction, small group tutoring, large-format classes, and assessments. Its flagship business operates under the Varsity Tutors brand. The company's offerings are available directly to students and consumers, as well as through schools and other institutions.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.